Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

5.280
-0.060-1.12%
Volume:446.12K
Turnover:2.39M
Market Cap:4.30B
PE:-22.59
High:5.550
Open:5.190
Low:5.190
Close:5.340
52wk High:9.340
52wk Low:4.040
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:1.25
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.234
ROE:-3.45%
ROA:-1.93%
PB:1.02
PE(LYR):-22.59
PS:3.94

Loading ...

HK Market Alert: Biocytogen-B (02315) Surges Over 10% in Afternoon Trade Following Exclusive Licensing Agreement with Qilu Pharmaceutical

Stock News
·
Sep 08

Hong Kong Market Pulse | CRO Shares Advance as Order Growth Strengthens; AI-Enabled Drug Discovery Poised to Transform Pharma R&D

Stock News
·
Sep 08

Riding on One-Off Licensing Income, Suzhou Zelgen's Hong Kong Listing Ambitions Face Scrutiny Amid First Post-IPO Semi-Annual Profit

Stock News
·
Sep 07

Hong Kong Stock Market Flash | METIS TECHBIO-P (07666) Surges Over 15% in Morning Session, Leading the AI Drug Development Sector as AI4S Commercialization Picks Up Pace

Stock News
·
Sep 07

Suzhou Zelgen's New Thyroid Cancer Treatment Application Accepted by Regulators

Stock News
·
Sep 06

Critical Safety Flaws in Huatai Pharmaceutical's Emergency Drug Lead to Exclusion from National Procurement Program

Deep News
·
Sep 05

AI Integration Becomes Essential for Biopharma's Future, Says Henlius CEO

Deep News
·
Sep 05

Ocumension Posts Stable Share Capital Structure for August 2026; Confirms Public-Float Compliance

Bulletin Express
·
Sep 04

OCUMENSION-B Completes Patient Enrollment in Phase III Trial of Dry Eye Treatment

Stock News
·
Sep 02

Ocumension Completes Enrollment in China Phase III Trial of Dry Eye Drug OT-211

Reuters
·
Sep 02

歌礼制药-B股价早盘攀升逾8%,重磅减肥药全球III期试验迎来关键里程碑

Deep News
·
Sep 02

Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted by NMPA

Reuters
·
Sep 02

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Stock News
·
Sep 01

Ocumension Therapeutics' Application for Ocular Inflammation Drug Accepted in China

MT Newswires Live
·
Sep 01

Ocumension Therapeutics - Application for Dexamethasone Intraocular Suspension Accepted by Nmpa as Class 4 Chemical Drug

THOMSON REUTERS
·
Sep 01

Ocumension Says China Regulator Accepts Domestic Filing for Dexamethasone Eye Injection OT-502

Reuters
·
Sep 01

Ocumension Therapeutics - Acceptance of Application for Drug Registration of Domestically Produced Dexamethasone Intraocular Suspension

THOMSON REUTERS
·
Sep 01

Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise

Stock News
·
Sep 01

Trump Administration’s Medicaid Drug Pricing Deal Set to Stir Asian Pharma Stocks

Deep News
·
Sep 01

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Stock News
·
Aug 31